Scioto Biosciences Announces Publication of Phase 1b Study in Autism
FISHERS, Ind.--(BUSINESS WIRE)--Scioto Biosciences, Inc. (Scioto), a clinical-stage biotechnology company dedicated to innovative research and development in the field of microbiome therapeutics for various diseases, announced top-line results of its Phase Ib trial of lead asset, SB-121, based on its novel microbiome delivery platform, Activated Bacterial Therapeutics (ABT), which is designed to deliver best-in-class, live therapeutic bacteria to the gut.
INDIANAPOLIS--(BUSINESS WIRE)--Scioto Biosciences, Inc. announced the beginning of their Phase Ib clinical trial for their lead investigational product SB-121 for the treatment of Autistic Disorder (AD). The first patient was randomized and started dosing in mid-August. Scioto is an innovation-driven biotechnology company focused on developing a novel microbiome platform called Activated Bacterial Therapeutics (ABT). SB-121 is the first ever ABT to be tested in the clinic.